Mostafa F Mohammed Saleh,Abdulrahman Nasiri,Mahmoud Aljurf et al.
Mostafa F Mohammed Saleh et al.
Sequential CLAGE-Ven (cladribine, cytarabine, etoposide, and venetoclax) with reduced-intensity conditioning improves outcomes in patients with refractory acute myeloid leukemia: a prospective phase II study [0.03%]
序贯CLAGE-Ven（克拉屈滨、阿糖胞苷、依托泊苷和维奈托克）联合减剂量预处理方案可改善复发/难治急性髓系白血病患者的预后：一项前瞻性II期临床试验
Wen-Hui Gao,Chu-Ran Wang,Li-Ning Wang et al.
Wen-Hui Gao et al.
Integrated transcriptomic and TCR profiling reveals local immune dysregulation of T cells in Gl aGvHD [0.03%]
整合转录组和TCR谱系揭示Gl aGvHD中T细胞局部免疫失调
Manisha Goel,Anne Eugster,Susanne Reinhardt et al.
Manisha Goel et al.
Reconsidering the role of bone marrow as a graft source in haploidentical allogeneic hematopoietic cell transplantation [0.03%]
单倍型相合造血干细胞移植骨髓作为植入来源的研究思考
Nihar Desai,Jonas Mattsson,Arjun D Law
Nihar Desai
A phase II multicenter prospective study to evaluate the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning regimen in allogeneic hematopoietic stem cell transplantation for AML patients aged 40-65 in first complete remission [0.03%]
异基因造血干细胞移植清淋预处理方案中高剂量化疗药物三氧化硫联合氟达拉滨(FT14)应用于40-65岁首次完全缓解成人AML患者的II期多中心前瞻性研究
Daniele Avenoso,Vera Radici,Alessandro Leoni et al.
Daniele Avenoso et al.
Evidences supporting the use of myeloablative-dose Treosulfan combined with Fludarabine remain largely retrospective, with outdated prospective studies available. In this phase II multicenter prospective trial, we evaluated the safety and e...
Safety, efficacy and feasibility of GCSF and plerixafor based CD34 mobilization for backup autologous stem cell collection in patients undergoing alternate donor hematopoietic stem cell transplant for sickle cell disease: Take away lessons for gene therapy [0.03%]
G-CSF和plerixafor动员结合CD34预处理，用于镰状细胞疾病allo-HSCT患者的备用车厢自体干细胞采集的安全性、有效性和可行性：基因治疗的启示
Garima Nirmal,Vaibhav Chadha,Shruti Verma et al.
Garima Nirmal et al.
A retrospective analysis was performed on 70 patients with SCD aged 3 million/ Kg recipient body weight was collected. Median age of cohort was 10 years (1-27 years). Median CD34 dose per collection was 7.7 × 106/ kg recipient body weight...
Fecal calprotectin as a biomarker for the diagnosis of gastrointestinal graft-versus-host disease following allogeneic hematopoietic stem cell transplantation [0.03%]
人脐带血移植后肠道移植物抗宿主病的粪便Calprotectin标志物检测及其临床意义研究
C Piñero-Pérez,A Velasco-Guardado,E Pérez-López et al.
C Piñero-Pérez et al.
Gastrointestinal graft-versus-host disease (GI-GVHD) is a major complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT), often requiring invasive endoscopy for diagnosis. Fecal calprotectin (FC) offers a non-invasi...
Bendamustine-based lymphodepletion prior to CAR T-cell therapy: a systematic review [0.03%]
基于苯达莫司汀的CAR-T细胞治疗前淋巴耗竭：系统性综述
Mostafa F Mohammed Saleh,Ahmed Abdrabou,Ahmed Alnughmush et al.
Mostafa F Mohammed Saleh et al.
Lymphodepletion (LD) is a critical prerequisite for successful chimeric antigen receptor T-cell (CAR-T) therapy. While fludarabine and cyclophosphamide (Flu/Cy) remain the standard LD regimen, bendamustine has emerged as a potential alterna...
Autologous stem cell transplantation for AL amyloidosis: a multicenter summary of outcomes 2010-2020 [0.03%]
自体干细胞移植治疗AL型淀粉样变病的多中心疗效总结（2010-2020）
Ben Lerman,Stefan Schönland,Ute Hegenbart et al.
Ben Lerman et al.
The role of autologous stem cell transplantation (ASCT) is central in AL amyloidosis and continues to be defined in the era of newer therapies. To evaluate contemporary patient selection, practice patterns, and outcomes, we conducted a retr...
Non-myeloablative versus reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients aged ≥65: a study from the ALWP of EBMT [0.03%]
老年（≥65岁）急性髓系白血病患者非清淋与减低强度预处理allo-HSCT的比较：来自EBMT ALWP的研究
A Kanellopoulos,M Labopin,A Spyridonidis et al.
A Kanellopoulos et al.
The optimal conditioning intensity for allogeneic hematopoietic stem cell transplantation (allo-HCT) in elderly acute myeloid leukemia (AML) remains elusive. We retrospectively analyzed 2900 AML patients aged ≥65 in complete remission who ...